ABSSSI Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Glenmark Pharma, Melinta Therapeutics, Sandoz Inc, Paratek Pharma, AbbVie Inc., Allergan PLC, Merck & Co. Inc., Pfizer

The Key Acute Bacterial Skin and Skin-Structure Infection Companies in the market include - Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharma, and others.

DelveInsight's "Acute Bacterial Skin and Skin-Structure Infection Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Acute Bacterial Skin and Skin-Structure Infection, historical and forecasted epidemiology as well as the Acute Bacterial Skin and Skin-Structure Infection market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Acute Bacterial Skin and Skin-Structure Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acute Bacterial Skin and Skin-Structure Infection Market Forecast [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Acute Bacterial Skin and Skin-Structure Infection Market Report:

*
The Acute Bacterial Skin and Skin-Structure Infection market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

*
In May 2025, Absci Corporation (NASDAQ: ABSI), a clinical-stage biopharmaceutical company leveraging generative AI to develop innovative therapeutics, announced that the first healthy volunteers have been dosed in a randomized, placebo-controlled Phase 1 trial of ABS-101, an investigational anti-TL1A antibody designed using Absci's generative AI platform. ABS-101 is optimized for quarterly subcutaneous administration, demonstrates enhanced potency against both monomeric and trimeric TL1A, and carries a lower immunogenicity risk, potentially improving efficacy, patient convenience, and adherence. Interim safety, pharmacokinetics/pharmacodynamics (PK/PD), and immunogenicity results are anticipated in the second half of 2025.

*
In April 2025, Sydney-based Recce Pharmaceuticals has raised A$5.0 million through a private placement and initiated a A$10.8 million entitlement offer to fund Phase 3 trials of its synthetic anti-infective treatments targeting diabetic foot infections (DFI) and acute bacterial skin and skin structure infections (ABSSSI).

*
In February 2025, Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), a company specializing in developing a novel class of synthetic anti-infectives, has reported positive results from its Phase II trial assessing RECCE Registered 327 Topical Gel (R327G) for treating acute bacterial skin and skin structure infections (ABSSSI).

*
In October 2024, Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), a company focused on developing a new class of synthetic anti-infectives, announced that an independent non-Data Safety Monitoring Board (non-DSMB) has completed its review of the safety and efficacy data from the ongoing Phase II clinical trial of its lead compound, RECCE Registered 327 Gel (R327G), in patients with acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot infections (DFI).

*
Basilea Pharmaceutica's Zevtera (ceftobiprole medocaril sodium for injection), an antibiotic approved by the US Food and Drug Administration (FDA), is used to treat a range of infections. It is specifically recommended for adults with bloodstream infections caused by Staphylococcus aureus (SAB) and acute bacterial skin and skin structure infections (ABSSSI).

*
ABSSSI, or Acute Bacterial Skin and Skin-Structure Infections, are a collection of bacterial infections impacting the skin and its related structures, including subcutaneous tissue and muscle. They vary in severity and are primarily caused by bacterial agents.

*
According to a secondary analysis, ABSSSI was responsible for nearly 870,000 hospital admissions in the United States in 2004, reflecting a nearly 30% increase in the incidence of this diagnosis over a four-year period.

*
Key Acute Bacterial Skin and Skin-Structure Infection Companies: Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others

*
Key Acute Bacterial Skin and Skin-Structure Infection Therapies: Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others

*
The Acute Bacterial Skin and Skin-Structure Infection epidemiology based on gender analyzed that the incidence of Acute Bacterial Skin and Skin-Structure Infection is higher in men than women

*
The Acute Bacterial Skin and Skin-Structure Infection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acute Bacterial Skin and Skin-Structure Infection pipeline products will significantly revolutionize the Acute Bacterial Skin and Skin-Structure Infection market dynamics.

Acute Bacterial Skin and Skin-Structure Infection Overview

Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) are infections that affect the skin and underlying tissues, caused by bacteria. Common types include cellulitis, abscesses, and infected wounds. Symptoms often include redness, swelling, warmth, pain, and sometimes fever. These infections can be serious, especially if left untreated, and may spread to deeper tissues or the bloodstream. They are typically treated with antibiotics, and in some cases, surgical drainage may be required for abscesses. People with weakened immune systems or chronic conditions like diabetes are at higher risk of developing ABSSSI.

Get a Free sample for the Acute Bacterial Skin and Skin-Structure Infection Market Report:

https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market [https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Bacterial Skin and Skin-Structure Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Acute Bacterial Skin and Skin-Structure Infection Epidemiology Segmentation:

The Acute Bacterial Skin and Skin-Structure Infection market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Acute Bacterial Skin and Skin-Structure Infection

*
Prevalent Cases of Acute Bacterial Skin and Skin-Structure Infection by severity

*
Gender-specific Prevalence of Acute Bacterial Skin and Skin-Structure Infection

*
Diagnosed Cases of Episodic and Chronic Acute Bacterial Skin and Skin-Structure Infection

Download the report to understand which factors are driving Acute Bacterial Skin and Skin-Structure Infection epidemiology trends @ Acute Bacterial Skin and Skin-Structure Infection Epidemiology Forecast [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Bacterial Skin and Skin-Structure Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Acute Bacterial Skin and Skin-Structure Infection market or expected to get launched during the study period. The analysis covers Acute Bacterial Skin and Skin-Structure Infection market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Acute Bacterial Skin and Skin-Structure Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Acute Bacterial Skin and Skin-Structure Infection Therapies and Key Companies

*
Contezolid acefosamil: MicuRx

*
Zevtera: Basilea Pharmaceuticals

*
Iclaprim: Motif Bio

*
Levonadifloxacin: Wockhardt

*
Dalbavancin: Allergan

*
ceftobiprole medocaril: Basilea Pharmaceutical

*
Tedizolid phosphate: Merck Sharp & Dohme LLC

*
linezolid: Arrevus Inc.

*
Oritavancin: The Medicines Company

*
NXL103: Novexel Inc

*
Daptomycin: PolyMedix, Inc.

*
Xydalba: Hippocrates Research

*
Kimyrsa: Melinta Therapeutics, Inc.

Discover more about therapies set to grab major Acute Bacterial Skin and Skin-Structure Infection market share @ Acute Bacterial Skin and Skin-Structure Infection Treatment Market [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Acute Bacterial Skin and Skin-Structure Infection Market Drivers

*
Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)(AATD) is a complex disorder, efforts have been made by researchers and scientific professionals to improve the understanding of the pathogenesis and diagnosis of this condition

*
Treatment of AATD has improved significantly in recent years with the availability of several safe and effective therapies. Several consensus guidelines have been created to further assist in the management of patients

Acute Bacterial Skin and Skin-Structure Infection Market Barriers

*
Need of novel and effective treatment for Acute Bacterial Skin and Skin-Structure Infection.

*
Need to develop management guidelines for patients with Acute Bacterial Skin and Skin-Structure Infection (ABSSSI)

*
Need for reassessment of doses for ABSSSI

Scope of the Acute Bacterial Skin and Skin-Structure Infection Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Acute Bacterial Skin and Skin-Structure Infection Companies: Glenmark Pharmaceuticals Ltd, Melinta Therapeutics Inc., Sandoz Inc. (a subsidiary of Novartis), Paratek Pharmaceuticals Inc., AbbVie Inc. (Allergan PLC), Merck & Co. Inc., Pfizer Inc., Melinta Therapeutics Inc., MicuRx, Basilea Pharmaceuticals, Motif Bio, Wockhardt, Allergan, Basilea Pharmaceutical, Arrevus Inc., The Medicines Company, Novexel Inc, PolyMedix, Inc., Hippocrates Research, and others

*
Key Acute Bacterial Skin and Skin-Structure Infection Therapies: Contezolid acefosamil, Zevtera, Iclaprim, Levonadifloxacin, Dalbavancin, ceftobiprole medocaril, Tedizolid phosphate, linezolid, Oritavancin, NXL103, Daptomycin, Xydalba, Kimyrsa, and others

*
Acute Bacterial Skin and Skin-Structure Infection Therapeutic Assessment: Acute Bacterial Skin and Skin-Structure Infection current marketed and Acute Bacterial Skin and Skin-Structure Infection emerging therapies

*
Acute Bacterial Skin and Skin-Structure Infection Market Dynamics: Acute Bacterial Skin and Skin-Structure Infection market drivers and Acute Bacterial Skin and Skin-Structure Infection market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Acute Bacterial Skin and Skin-Structure Infection Unmet Needs, KOL's views, Analyst's views, Acute Bacterial Skin and Skin-Structure Infection Market Access and Reimbursement

To know more about Acute Bacterial Skin and Skin-Structure Infection companies working in the treatment market, visit @ Acute Bacterial Skin and Skin-Structure Infection Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/acute-bacterial-skin-and-skin-structure-infections-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Acute Bacterial Skin and Skin-Structure Infection Market Report Introduction

2. Executive Summary for Acute Bacterial Skin and Skin-Structure Infection

3. SWOT analysis of Acute Bacterial Skin and Skin-Structure Infection

4. Acute Bacterial Skin and Skin-Structure Infection Patient Share (%) Overview at a Glance

5. Acute Bacterial Skin and Skin-Structure Infection Market Overview at a Glance

6. Acute Bacterial Skin and Skin-Structure Infection Disease Background and Overview

7. Acute Bacterial Skin and Skin-Structure Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Acute Bacterial Skin and Skin-Structure Infection

9. Acute Bacterial Skin and Skin-Structure Infection Current Treatment and Medical Practices

10. Acute Bacterial Skin and Skin-Structure Infection Unmet Needs

11. Acute Bacterial Skin and Skin-Structure Infection Emerging Therapies

12. Acute Bacterial Skin and Skin-Structure Infection Market Outlook

13. Country-Wise Acute Bacterial Skin and Skin-Structure Infection Market Analysis (2020-2034)

14. Acute Bacterial Skin and Skin-Structure Infection Market Access and Reimbursement of Therapies

15. Acute Bacterial Skin and Skin-Structure Infection Market Drivers

16. Acute Bacterial Skin and Skin-Structure Infection Market Barriers

17. Acute Bacterial Skin and Skin-Structure Infection Appendix

18. Acute Bacterial Skin and Skin-Structure Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=absssi-market-to-reach-new-heights-in-growth-by-2034-delveinsight-predicts-glenmark-pharma-melinta-therapeutics-sandoz-inc-paratek-pharma-abbvie-inc-allergan-plc-merck-co-inc-pfizer]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.